<DOC>
	<DOCNO>NCT01521494</DOCNO>
	<brief_summary>To investigate dose-response efficacy safety hemodialysis patient hyperphosphatemia .</brief_summary>
	<brief_title>PA21 Phase II Clinical Study Hemodialysis Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients age 20 old , regardless gender . Receiving stable maintenance hemodialysis 3 time week . Patients change phosphate binder agent dose , 4 week observation period start . Patients history pronounce brain / cardiovascular disorder . Patients severe gastrointestinal disorder . Patients severe hepatic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>